M
Martin Proescholdt
Researcher at University Hospital Regensburg
Publications - 129
Citations - 4305
Martin Proescholdt is an academic researcher from University Hospital Regensburg. The author has contributed to research in topics: Medicine & Glioma. The author has an hindex of 29, co-authored 107 publications receiving 3712 citations. Previous affiliations of Martin Proescholdt include National Institutes of Health & University of Regensburg.
Papers
More filters
Journal ArticleDOI
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Dagmar Beier,Peter Hau,Martin Proescholdt,Annette Lohmeier,Jörg Wischhusen,Peter J. Oefner,Ludwig Aigner,Alexander Brawanski,Ulrich Bogdahn,Christoph P. Beier +9 more
TL;DR: Together, the data provide first evidence that CD133(+) CSC maintain only a subset of primary glioblastomas, with apparent stem cell-like properties but distinct molecular profiles and growth characteristics in vitro and in vivo.
Journal ArticleDOI
Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Dagmar Beier,Stefanie Röhrl,Deepu R. Pillai,Stefanie Schwarz,Leoni A. Kunz-Schughart,Petra Leukel,Martin Proescholdt,Alexander Brawanski,Ulrich Bogdahn,Ariane Trampe-Kieslich,Bernd Giebel,Jörg Wischhusen,Guido Reifenberger,Peter Hau,Christoph P. Beier +14 more
TL;DR: The data strongly suggest that optimized temozolomide-based chemotherapeutic protocols might substantially improve the elimination of GBM stem cells and consequently prolong the survival of patients.
Journal ArticleDOI
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.
Peter Hau,Piotr Jachimczak,Reimar Schlingensiepen,Frank J. Schulmeyer,Tanya Jauch,Andreas Steinbrecher,Alexander Brawanski,Martin Proescholdt,J. Schlaier,Johanna Buchroithner,Josef Pichler,Gabriele Wurm,Maximilian Mehdorn,Rainer Strege,Gerhard Schuierer,Victoria Villarrubia,Franz A. Fellner,Olav Jansen,Thorsten Straube,Virinder Nohria,Michael Goldbrunner,Mechthild Kunst,S. Schmaus,Gerhard Stauder,Ulrich Bogdahn,Karl-Hermann Schlingensiepen +25 more
TL;DR: Results implicate targeted TGF-beta2-suppression using AP 12009 as a promising novel approach for malignant gliomas and other highly aggressive, T GF-beta-2-overexpressing tumors.
Journal ArticleDOI
Sodium fluorescein-guided resection under the YELLOW 560 nm surgical microscope filter in malignant brain tumor surgery--a feasibility study.
Karl-Michael Schebesch,Martin Proescholdt,Julius Höhne,Christoph Hohenberger,Ernil Hansen,Markus J. Riemenschneider,Winfried Ullrich,Christian Doenitz,Juergen Schlaier,Max Lange,Alexander Brawanski +10 more
TL;DR: The use of FL for the resection of brain tumors is safe and feasible, and the intensity of the fluorescence signal seemed to be correlated to the histology and was strongly dependent on the pre-treatment status.
Journal ArticleDOI
CD133 Expression and Cancer Stem Cells Predict Prognosis in High‐grade Oligodendroglial Tumors
Dagmar Beier,Jörg Wischhusen,Wolfgang Dietmaier,Peter Hau,Martin Proescholdt,Alexander Brawanski,Ulrich Bogdahn,Christoph P. Beier +7 more
TL;DR: This series correlated the presence of putative cancer stem cells (CSC) in high‐grade oligodendroglial tumors (WHO grades III and IV) with clinical outcome and predicted clinical outcome more reliable than the histological assessment.